Blinatumomab Clinical Trials
43 recruitingDrug
Phase 227Phase 112Phase 39Not Applicable4Phase 41
Showing 1–20 of 43 trials
Recruiting
Phase 2
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)222 enrolled148 locationsNCT06124157
Recruiting
Phase 2
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Acute Leukemia of Ambiguous LineageB Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)153 enrolled109 locationsNCT06317662
Recruiting
Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)84 enrolled276 locationsNCT03739814
Recruiting
Phase 2Phase 3
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
B-cell Acute Lymphoblastic Leukemia
Merck Sharp & Dohme LLC340 enrolled3 locationsNCT07570173
Recruiting
Phase 2
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma
M.D. Anderson Cancer Center80 enrolled1 locationNCT02877303
Recruiting
Phase 2
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Leukemia
M.D. Anderson Cancer Center27 enrolled1 locationNCT05645718
Recruiting
Phase 2
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+5 more
M.D. Anderson Cancer Center90 enrolled1 locationNCT03263572
Recruiting
Phase 1Phase 2
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive
M.D. Anderson Cancer Center40 enrolled2 locationsNCT06308588
Recruiting
Not Applicable
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China110 enrolled1 locationNCT07493161
Recruiting
Not Applicable
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, Adult
Institute of Hematology & Blood Diseases Hospital, China43 enrolled1 locationNCT07495631
Recruiting
Not Applicable
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Acute Lymphoblastic LeukemiaPh-Like
Institute of Hematology & Blood Diseases Hospital, China92 enrolled1 locationNCT07454226
Recruiting
Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen304 enrolled192 locationsNCT04994717
Recruiting
Phase 2
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis
Amgen220 enrolled54 locationsNCT06570798
Recruiting
Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma+2 more
Children's Oncology Group5,951 enrolled230 locationsNCT03959085
Recruiting
Phase 3
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Leukemia, Acute Lymphoblastic
Mats Heyman6,430 enrolled138 locationsNCT04307576
Recruiting
Phase 2
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center60 enrolled1 locationNCT07153796
Recruiting
Phase 2
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
St. Jude Children's Research Hospital128 enrolled2 locationsNCT06533748
Recruiting
Phase 1Phase 2
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
B Cell Precursor Acute Lymphoblastic Leukemia
Amgen281 enrolled109 locationsNCT04521231
Recruiting
Phase 2
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
The First Affiliated Hospital of Soochow University101 enrolled1 locationNCT07564453
Recruiting
Phase 1Phase 2
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Amgen104 enrolled4 locationsNCT07134088